Full View

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial

JH Butt, JC Nicolau, S Verma… - European journal of …, 2021 - Wiley Online Library
Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …
被引用次数：42 相关文章

[引用][C] Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH Butt, JC Nicolau, S Verma, KF Docherty… - European journal of …, 2021 - repositorio.usp.br
ReP USP - Detalhe do registro: Efficacy and safety of dapagliflozin according to aetiology in
heart failure with reduced ejection fraction: insights from the DAPA-HF trial Home About USP …

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.

JH Butt, JC Nicolau, S Verma, KF Docherty… - European Journal of …, 2021 - europepmc.org
Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …
[PDF] dapatrial.org

[PDF][PDF] Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH Butt, JC Nicolau, S Verma, KF Docherty… - European Journal of …, 2021 - dapatrial.org
Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH Butt, JC Nicolau, S Verma, KF Docherty… - European Journal of …, 2021 - eprints.gla.ac.uk
Aims: We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH Butt, JC Nicolau, S Verma, KF Docherty, MC Petrie… - 2021 - pubmed.ncbi.nlm.nih.gov
Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH BUTT, JC NICOLAU, S VERMA… - … Journal of Heart …, 2021 - observatorio.fm.usp.br
Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH Butt, JC Nicolau, S Verma, KF Docherty, MC Petrie… - ikm.ku.dk
Aims: We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial

JH Butt, JC Nicolau, S Verma… - European Journal of …, 2021 - research.regionh.dk
AIMS: We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …